AHN-GOOK PHARMACEUTICAL's largest shareholder Eo Jin increases pledged shares to 18.54% through new collateral contracts, raising governance risk from potential margin calls
AHN-GOOK PHARMACEUTICAL's largest shareholder and CEO Eo Jin filed a change report on substantial shareholding as of June 30, 2026.
His total shareholding remains unchanged at 6,288,699 shares representing 48.22% ownership, but new pledge agreements with Nonghyup Bank and Meritz Securities increased total pledged shares to 2,419,377 shares or 18.54% of outstanding shares, up from 17.86%.
The new pledges are for personal loans of 1 billion KRW and 350 million KRW, with maintenance ratios of 120% to 200%, creating risk of margin calls or forced selling if the stock price declines.
Including existing tax installment pledges of 1.87 million shares, the expanded collateral base raises governance concerns as the largest shareholder's financial stress could impair voting rights.
[AI Summary]AHN-GOOK PHARMACEUTICAL's largest shareholder Eo Jin increased his stock pledge ratio to 18.54% by entering new collateral contracts for personal financing. The short-term loans and maintenance ratio conditions expose the stock to forced sale risk if prices fall below trigger levels. At the current price of 9,900 KRW and market cap of 129.1 billion KRW, additional margin calls could create downward pressure on the stock.